17,261 trials
Graft Versus Host Disease · GVHD
Primary: Incidence of Grade II-IV Acute GVHD (aGVHD) Developing by Day 100 Following Non-myeloablative PBSC Transplantation Using Tacrolimus and Sirolimus. — 5 participants
Thalassemia
Primary: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL — 2 participants
Cat Allergy
Primary: The the Size of the 8 Late-phase Skin Response — 54; 0 percentage decline from NAC-1
Colorectal Cancer · Metastatic Cancer
Primary: Recurrence-free Survival at 2 Years — 13; 10 participants
Prostate Cancer
Primary: Percentage of Patients Needing a Dose Reduction. — 71 percentage of participants
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Prostate Cancer
Primary: Overall Clinical Benefit From Torisel® in Chemotherapy-naïve Castration Resistant Prostate Cancer (CRPC). — 67 percentage of participants
Tobacco Use Cessation · Alcohol-related Disorders
Primary: Smoking Abstinence — 20; 1 participants — p=<.01
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response — 0; 3; 0; 2 participants
Allergy
Primary: Scores on a Scale (Average of Total Symptom Scores) — 7.02; 8.30; 7.87 Scores on a scale — p=<0.05
Age Related Macular Degeneration
Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters
Acute Coronary Syndrome (ACS)
Primary: Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay…
Metastatic Breast Cancer
Primary: Dose Limiting Toxicity (DLT) — 5 Dose Limiting Toxicities
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants